[ET Net News Agency, 31 July 2020] Sino Biopharmaceutical Limited (01177) announced
that "Tofacitinib Citrate Tablet" (brand name: Weijie), a drug for the treatment of
rheumatoid arthritis developed by the group, has obtained drug registration certificate
granted by the National Medical Products Administration of the People's Republic of China
and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for
Generic Drugs.
Tofacitinib Citrate Tablet is suitable for adult patients with moderately to severely
active rheumatoid arthritis for whom methotrexate does not work well or who are intolerant
of methotrexate. It can be used in combination with methotrexate or other non-biological
anti-rheumatic drugs to improve the condition. (RC)